In agreement with that, SREBP1c and key DNL enzymes were found to be upregulated at the transcriptional level in patients with MASLD as well as in cell culture and animal models of MASLD (35, 36). Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.